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The thesis explained 
Cardiovascular diseases (CVDs) are still the leading cause 
of death and disabilities globally. Among CVDs, ischemic heart 
disease (IHD) has remained the leading cause of death worldwide 
in the last 16 years. IHD is caused by a sudden blockage of blood 
flow through coronary arteries that prevents the supply of oxygen 
and nutrients to the region of myocardium fed by the affected 
vessels. This condition causes the necrosis of the myocardium that 
is followed by a reparative process that starts from the infarcted 
area, but then involves, at later stages, also the uninjured 
myocardium, causing progressive fibrosis that may lead eventually 
to heart failure. Unfortunately, there is no cure for IHD and therapy 
can at best control symptoms and prevent a second ischemic event. 
The induction of post-infarction cardiac regeneration by the means 
of three factors, cells, scaffold and signals, is currently the target of 
cardiac tissue engineering. However, the field is still at its infancy 
and all three factors are yet to be defined. Since the ECM is the 
naturally occurring scaffold loaded with uncountable biological 
and mechanical signals, we aimed at obtaining and characterizing a 
biological three-dimensional scaffold for cardiac repair and 
regeneration from the adult human skin.  
Our results provided evidence that the scaffold of 
decellularized human skin (d-HuSk) was acellular and had a 
preserved architecture, retained components of the ECM that are 
also typical of cardiac matrix and are critical for cardiac functions 
and mechanical properties of the ECM, like collagen, fibronectin, 
laminin, tenascin, elastin and GAGs. Additionally, growth factors 
stored in d-HuSk matrix were similar to those found in cardiac 
matrix and, as similar were the signals, similar were the effects of 
d-HuSk and cardiac matrix on human cardiac progenitor cells 
(hCPCs). Indeed, as emerged from cytocompatibility study, the 
environment offered by d-HuSk did not differ from the cardiac 
native one in supporting engraftment and survival of hCPCs. 
Furthermore, d-HuSk attracted hCPCs from the cardiac native 
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matrix and sustained their differentiation and differentiation 
towards cardiac myocytes. 
Therefore, d-HuSk is a biological scaffold that is easily 
obtained and might be used as an autograft. It shares to a large 
extent the composition of the cardiac native matrix, exerts on 
hCPCs similar effects in vitro and is also capable of stimulating 
their mobilization and engraftment. Overall, d-HuSk fulfills the 
key requirements needed for a scaffold to warrant its use in tissue 
engineering and, then, holds great promise as substitute for cardiac 
environment. Additionally, consisting of ECM proteins and being a 
storage of growth factors, d-HuSk might alone provide two of the 
three pillars of tissue engineering, namely the scaffold and the 
signals, and might be exploited as stand-alone scaffold to boost 
cardiac regeneration by recruiting resident cardiac progenitor cells, 
or as a cellularized scaffold by preparing a cardiac engineered 
tissue in vitro with the cell population of choice. 
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1 Introduction 
1.1 Cardiovascular diseases 
1.1.1 Definition 
Cardiovascular diseases (CVDs) are disorders of the heart 
and blood vessels that include coronary heart disease, 
cerebrovascular disease, peripheral arterial disease, rheumatic heart 
disease, congenital heart disease and deep vein thrombosis and 
pulmonary embolism (1). CVDs and other chronic diseases like 
chronic respiratory diseases and diabetes are classified by World 
Health Organization (WHO) as non-communicable diseases 
(NCDs).  
1.1.2 Epidemiology and risk factors 
Based upon WHO computations, NCDs are responsible 
every year for 41 million deaths that account for 71% of all deaths 
globally (2). Remarkably though, cardiovascular diseases (CVDs), 
cancers, chronic respiratory diseases, and diabetes collectively 
account for 70% of all NCD deaths, while CVDs alone are 
responsible for 31% of all deaths worldwide (1). Furthermore, 
CVDs are major contributors to overall disease burden, expressed 
as the disability-adjusted life year (DALY), which is a measure of 
both the quality of life and the life expectancy of affected patients 
expressing the number of years of life lived with disability (YLDs) 
and years of life lost (YLLs) due to ill-health.  
Among CVDs ischemic heart disease (IHD) was 
responsible for more than 15% of all deaths in all countries from 
the low-income to the high-income economies in 2016. Although 
most IHD deaths can be prevented or delayed by addressing 
behavioral risk factors, they continue to be an important public 
health challenge in all countries and IHD has remained the leading 
cause of death in countries ranging from lower-middle to high 
income in the last 16 years (Fig. 1) (3).  
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Figure 1. Top 10 causes of death worldwide. Major causes of death globally in 
2000 (graph on the top) and in 2016 (graph on the bottom). Ischemic heart 
disease has remained the leading cause of death worldwide for the last 16 years 
(http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death). 
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However, this difference is likely due to the great variation 
in life expectancy, since people from poorer countries die from 
other conditions before reaching an age where they would develop 
IHD (4).  
Behavioral risk factors, including tobacco use (5), 
unhealthy diet (6), lack of physical activity (7) and the harmful use 
of alcohol (8), lead in turn to obesity, diabetes, hypertension and 
high blood cholesterol (9). All these conditions dramatically 
increase the risk of developing CVDs (10-13). Hence, the burden 
of IHD can be effectively reduced by tackling modifiable 
behavioral risk factors (14). Governments have made strong 
political commitment to implement measures to reduce the harmful 
use of alcohol and to promote healthy diet and physical activity 
and to strengthen health systems through primary health care and 
universal health coverage interventions aimed at promoting and 
supporting healthier lifestyle. However, although the progress was 
tangible in western countries (15-17), it has been highly uneven. In 
fact, the burden of IHD is rising disproportionately among low-
income and lower-middle-income countries, due to other important 
risk factors like poverty, psychosocial status (18), low educational 
status, globalization of food industry, rapid urbanization and 
population growth (19). 
1.2 The Ischemic Heart Disease (IHD) 
IHD is due to coronary artery disease (CAD), a condition 
characterized by the formation of the atherosclerotic plaque within 
the wall of the vessels that feed the myocardium, namely the 
coronary arteries (Fig. 2, A). This process, termed atherosclerosis, 
occurs through the gradual accumulation of lipids in the vessel 
wall and involves inflammatory cells, endothelial cells and smooth 
muscle cells (20). Eventually, the plaque in a carotid artery hardens 
or ruptures and causes reduction or interruption of blood flow 
whose clinical manifestation is IHD.  
Myocardial infarction (MI) occurs when the blood flow is 
suddenly blocked more often due to the formation of a clot on a 
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ruptured atherosclerotic plaque. This blockage prevents the supply 
of oxygen and nutrients to the region of myocardium supplied by 
the affected arterial branch. If this condition persists it leads 
inexorably to the death of cardiac myocytes (Fig. 2, B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Coronary Artery Disease and Ischemic Heart Disease. Coronary 
artery disease is characterized by the formation of the atherosclerotic plaque 
within the wall of coronary artery (A). More often the myocardial infarction is 
caused by the rupture of a plaque and the formation of a clot that blocks the 
blood flow and prevents the supply of oxygen and nutrients to the myocardium 
fed by the involved vessel (B). 
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Due to the sudden ischemic death of cardiac myocytes as to 
the very limited regenerative ability of human myocardium, 
cardiac tissue damage triggers a series of complex events that leads 
to the reorganization of cardiac extracellular matrix (ECM) at site 
of injury and to the replacement of dead myocardium with 
permanent scar tissue. Such "local" early remodeling that involves 
the infarcted area occurs as a beneficial response to prevent 
ventricular wall rupture and is referred to as reparative or 
replacement fibrosis (Fig. 3). Specifically, tissue injury causes the 
releases of endogenous molecules known as alarmins (21) that are 
involved in cardiac repair by eliciting an inflammatory response 
that clears the necrotic area of degraded ECM and of dead cells. 
Furthermore, the release of soluble factors, like IL-1, IL-6 and 
TGF-beta 1, causes the activation of cardiac fibroblasts and their 
transdifferentiation to myofibroblasts (22) that synthesize and 
secrete large quantities of ECM proteins, including type I collagen, 
fibronectin, and tenascin C (23, 24). The formation of scar 
stabilizes the infarcted zone and the region immediately adjacent to 
it, but it also causes a dilation (25). However, cardiac remodeling 
following MI causes geometric changes that involve both the 
infarcted and non-infarcted myocardium (26, 27). Indeed, 
replacement fibrosis is followed by the remodeling of border zone 
and remote uninjured myocardium, where myocytes undergo 
hypertrophy in response to an unbalanced distribution of wall 
stress and ECM undergoes extensive rearrangement with excessive 
deposition of type I collagen, at the expense of the much less rigid 
type III collagen, to stabilize heart chambers and prevent further 
deformation. Such fibrotic response involves the left ventricle 
globally and is referred to as reactive or interstitial fibrosis (28) 
(Fig. 4).  
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Figure 3. Reparative or replacement fibrosis occurring after MI. Due to 
massive myocyte death, activated fibroblasts transdifferentiate into 
myofibroblasts, whose synthesis and deposition of a collagen-rich ECM leads to 
the replacement fibrosis (from JACC 2014;63:2188-2198). 
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Figure 4. Compensatory cardiac remodeling of the remote myocardium 
leads to the reactive fibrosis. The reparative fibrosis causes ventricular 
geometric changes that are responsible for an uneven distribution of mechanical 
forces through the myocardium. Healthy myocytes in regions remote to the 
infarcted area respond to such modified mechanical stimulation by undergoing 
hypertrophy, while fibroblasts are activated and synthesize excessive collagen. 
This fibrotic response, termed reactive or interstitial fibrosis, involves the left 
ventricle globally (from JACC 2014;63:2188-2198). 
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This progressive fibrosis occurring in the myocardium remote to 
the infarcted region disrupts myocardial architecture and have 
adverse effects on ventricular function (29). Therefore, the 
inflammatory response that is essential for cardiac repair is also 
implicated in the pathogenesis of post-infarction remodeling and 
may eventually lead to heart failure (30), a complex clinical 
syndrome caused by a structural or functional cardiac disorder that 
results in systolic or diastolic dysfunction responsible, in turn, for 
heart inability to perform sufficient pumping to meet body’s needs 
(31, 32). 
1.3 Current Treatment of IHD 
 
 Lifestyle changes, drugs, and medical procedures can help 
prevent or treat coronary heart disease.  
The initial therapy of MI is directed toward restoration of 
perfusion as soon as possible to limit myocyte loss. This may be 
accomplished through a pharmacological fibrinolysis in selected 
patients or by mechanical means, such as percutaneous coronary 
intervention (PCI), or coronary artery bypass graft (CABG) 
surgery.  
Successively, pharmacological therapy aimed at reducing 
mortality, relieve symptoms and signs, improve quality of life, 
prevent the occurrence of further myocardial damage and the 
remodeling of the myocardium is established.  
The medical therapy relies on several drugs, including anti-
thrombotic agents, vasodilator agents, beta-adrenoceptor 
antagonists (beta blockers), statins, diuretics, aldosterone receptor 
antagonists, angiotensin-converting enzyme (ACE) inhibitors, 
angiotensin II receptor blockers, whose combinations are dictated 
by the course of the disease and clinical conditions of the patients, 
as evaluated by follow-up (31-33). 
  Albeit considerable advances achieved in the understanding 
of the pathologic mechanisms of cardiac disease, modern therapies 
remain not curative, since the problem of cardiomyocyte loss has 
not yet been solved (34) and treatment can at best help to relieve 
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symptoms, reduce myocardial remodeling and the risk of having 
another ischemic event. 
As a result, the induction of post-infarction cardiac 
regeneration in adult mammals is currently the target of intensive 
research and drug discovery attempts.  
1.4 Future Treatment of IHD 
Regenerative medicine is aiming at restoring structure and 
function of damaged tissues and organs. The goal of this approach 
rises from the needing to develop a strategy to treat previously 
incurable injuries and highly deadly pathologies, as cardiovascular 
diseases (35). A combination of approaches and tools, such as 
tissue engineering, cellular therapies, and medical devices or 
artificial organs can enhance the healing process naturally 
occurring in human body as result of an injury (36). The close 
cooperation of diverse fields, like biology, chemistry, tissue 
engineering and even robotics is required to deal with such a 
challenging task (37). 
1.4.1 Cardiac Cell Therapy 
Cell therapy has been experimented for more than a decade, 
with a number of cell types used in clinical trials in seeking to 
replace damaged cells or to repair injured tissue (38).  
A pioneer study with the first cells used for cardiac 
regeneration, was performed in 1998 by Taylor et al. and 
demonstrated that skeletal myoblasts (SMs) have the ability to 
enhance and partially restore cardiac function (39). This study was 
an inspiration for the further use of many other cell types, such as 
bone marrow-derived stem cells (BMMNCs) (40-43), 
Mesenchymal stem cells (MSCs) (43), cardiac progenitor cells 
(CPCs) (44), cardiosphere-derived cells (CDCs) (45, 46), 
embryonic stem cells (ESCs) (47) and more recently induced 
pluripotent stem cells (iPSCs) (48, 49). There are still more 
controversies about the use of cells in therapy: on one hand they 
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produced encouraging results in improving the global cardiac 
function, and this is probably due to a paracrine action more than 
an effective integration and proliferation or survival in vivo, on the 
other hand the results of pre-clinical studies conducted in animal 
models and clinical trials conducted in humans were variable, not 
reproducible, and a number of obstacles and side effects were 
frequent (38).  
  One of the major obstacles about cell therapy was to find 
the appropriate way to deliver a sufficient number of cells to the 
damaged area in the less invasive way (34). Intracoronary and 
intramyocardial injection after myocardial infarction were the 
preferred strategies, even if the integration, the engraftment and the 
long-term survival of cells administrated was very weak (50). 
  An alternative to the direct injection of cells is the 
implantation of engineered tissue to offer a both mechanical and 
biological support to enhance cell retention and function in vivo 
(51). 
1.4.2 Cardiac Tissue Engineering 
  Tissue engineering technologies aim at the generation of 
three-dimensional tissue-like scaffolds for therapeutic use. Three 
factors are pivotal for a successful approach: cells, extracellular 
matrix, and biomimetic signals (52) (Fig. 5). 
  Scaffolds, in fact, require specific features to produce the 
desirable therapeutic outcome, as they have to guide cell 
organization, growth and differentiation, and have to ensure 
structural stability and a suitable environment where cells can 
produce new biological tissue (53). 
  Biocompatibility, biodegradability and appropriate 
mechanical properties are the major criteria used for the production 
of an engineered biological construct (52). 
  Biocompatibility is needed to avoid immune reactions 
undesirable for patients, and because cells must be attracted by the 
construct in order to adhere, proliferate and migrate like in a 
normal or natural microenvironment (54). 
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Figure 5. The tissue engineering triad. Tissue engineering strategies are based 
on three pillars: cells to rebuild the tissue, scaffolds to recreate the tissue 
environment and physical and chemical signals to support and stimulate cellular 
functions. 
A scaffold must be non-permanent and for this reason, 
biodegradability is a notable characteristic. In fact, once cells begin 
to produce their own new and healthy extracellular matrix, the 
scaffold is no more needed (52). 
It is crucial to customize the scaffold depending on the 
anatomical site of destination, in particular, mechanical properties 
and architecture must be balanced to guarantee the surgical 
handling during the implantation procedure and the adequate 
porosity to allow cell infiltration and vascularization (52). 
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 Several biomaterials, either natural or synthetic, have been 
tested thus far as substitute for cardiac environment to support cell-
based regeneration (55). 
 However, on the one hand the spatial organization of 
structural ECM components and the biochemical complexity of the 
ECM can be fully recapitulated only by the naturally occurring 
cardiac ECM, but, on the other hand, biomaterials are tunable in 
their physical properties that have been demonstrated to drive stem 
cell differentiation and behavior (56). Therefore, finding a 
substitute able to recapitulate, at least partially, mechanical and 
biological features of the myocardium is a primary goal in cardiac 
regenerative medicine. 
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2 Aims 
Cardiac cell therapy demonstrated that regeneration cannot 
occur without restoring the extracellular compartment along with 
the cellular compartment, as cell death causes a dramatic 
rearrangement of myocardial environment that triggers the 
replacement fibrosis and sustains the reactive fibrosis. The 
replacement of noncompliant scar tissue with newly formed and 
fully functional myocardium in the infarcted region would 
compensate the limited regenerative ability of human adult 
myocardium and oppose the pathological remodeling that 
inexorably takes place in the remote region of the ischemic heart.  
Cardiac tissue engineering promise to heal the infarcted 
heart relies on the combination of a scaffold with growth factors 
and cells. Scaffold and growth factors are employed to restore the 
microenvironment in its composition, architecture and signaling 
activity, while cells are needed to form new vessels and replace 
cardiac supporting and parenchymal cells. 
The aim of this study is to explore in vitro the possibility of 
constructing a three-dimensional scaffold for cardiac repair and 
regeneration from the adult human skin. The skin is the largest 
organ in the body that can be easily and opportunely harvested to 
provide a viable biological and autologous substitute for cardiac 
environment. Furthermore, cardiac and dermal ECMs are rich in 
collagen, laminin and elastin. Therefore, the decellularized human 
skin may also provide biological signals and mechanical 
properties, like elasticity, that are, at least partially, shared with the 
microenvironment of the myocardium. Based on the mounting 
evidence that the adult human heart hosts a population of resident 
cardiac progenitor cells, a scaffold carrying biological and 
mechanical signals might yet be used as stand-alone 
bioengineering product. 
To test our hypotheses, we prepared biological scaffold of 
decellularized human skin (d-HuSk) and decellularized human 
myocardium (d-HuM). Then, we evaluated whether d-HuSk 
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showed promise to serve as substitute for cardiac environment by 
analyzing its composition, biocompatibility and capability of 
delivering biological signals like the signals delivered by the native 
cardiac environment. Moreover, we analyzed in vitro the effects of 
d-HuSk on the engraftment and differentiation of resident cardiac 
progenitor cells to assess the potential of d-HuSk to serve as both 
cell-delivering and stand-alone scaffold. 
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3 Results and discussion 
3.1 The decellularization of human skin from living 
subjects can be swiftly and efficiently 
accomplished 
To be considered suitable for regenerative medicine 
applications, scaffolds of decellularized matrix should not elicit an 
immune response. This implies that decellularization process 
should ensure a complete removal of cellular antigens (57, 58). 
The currently accepted criteria to satisfy the intent of 
decellularization include a residual double-stranded DNA 
(dsDNA) content of less than 50 ng dsDNA per mg of dry 
decellularized tissue and lack of visible nuclear material in tissue 
sections stained with Hematoxylin and Eosin (H&E) (59). Snap-
frozen skin samples were decellularized following a recently 
published protocol proven successful for a fast and effective 
decellularization of human myocardium (60). The first obvious 
change that occurred with the decellularization was in the color of 
samples that turned completely white with the respect to the 
brownish color of native skin (Fig 6, A and B). Then quantitative 
measurements of DNA content and H&E staining were used to 
evaluate the effectiveness of decellularization and suitability of d-
HuSk as biological scaffold for tissue engineering, in accordance 
to aforementioned criteria. Analysis of DNA content clearly 
showed the virtual absence of dsDNA in d-HuSk (Fig 6, C), whose 
residual amounts were well below the currently accepted standard 
resulting as low as 7.50 ± 2.162 ng per mg of dry tissue (Fig 6, B). 
Such dramatic result was confirmed by the histological analysis as 
H&E staining demonstrated the absence of nuclei in d-HuSk (Fig. 
6, F) when compared with native skin (Fig. 6 E). Notably though, 
decellularization might be a very harsh treatment for soft tissues. 
The combination of chemical and mechanical methods of 
decellularization can cause both a biological impoverishment of 
the ECM and a disruption of tissue integrity and architecture (61).  
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Figure 6. Evaluation of the effectiveness of the decellularization procedure 
of skin. A and B: Representative images of macroscopic examination of native 
human skin (HuSk) (A) and decellularized human skin (d-HuSk) (B) showing an 
obvious change in color, inasmuch as d-HuSk samples were completely white. C 
and D: Representative gel electrophoresis revealing an extremely low content of 
residual dsDNA in d-HuSk (n = 6) with bands barely visible (C) and 
concentration of DNA well below that of the native skin (n = 4) and the 
proposed criterion of 50 ng (D). Data are expressed as mean ± SEM. (HS: native 
human skin, d-HS: d-HuSk). E and F: representative H&E image comparing 
native human skin (E) with d-HuSk (F) and confirming the effectiveness of 
decellularization as shown by the absence of nuclei in d-HuSk. (Scale bar: 50 
μm). 
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Therefore, it is crucial to find the right balance between strength, to 
ensure the complete removal of cells and debris, and subtlety, to 
avoid marked alteration of native structure and composition of 
matrix. Indeed, the histological analysis showed an overall well-
preserved architecture of the dermal matrix in d-HuSk (Fig 6, F). 
Therefore, d-HuSk not only fulfilled the requirements proposed for 
the evaluation of the effectiveness of decellularization, but also 
preserved the histological organization of native tissue, providing 
compelling evidence of a highly efficient decellularization method. 
3.2 Decellularized Human Skin (d-HuSk) consists of 
structural and functional ECM proteins that are 
key components of the cardiac matrix 
The ECM is a complex network of fibrous proteins, 
polysaccharides and soluble factors. On the one hand, the ECM is 
continuously produced and remodeled by resident cells, but, on the 
other hand, its unique composition and three-dimensional 
organization provide biological and mechanical cues that are 
responsible for directing stem cell fate (62) and cell behavior both 
in physiological and pathological states. Unquestionably, the ideal 
scaffold for cardiac regeneration would be the naturally occurring 
cardiac ECM and the most ambitious - and still unmet - aim of 
cardiac tissue engineering is to replicate its architecture and 
composition. Aiming at investigating on the suitability of d-HuSk 
as substitute for cardiac ECM, we evaluated by 
immunohistochemistry the presence and localization in d-HuSk of 
structural and non-structural proteins of the ECM (63) that are 
described as main components of both cardiac (64) and dermal 
matrix (65, 66) and that we previously reported as retained by 
decellularized cardiac matrix (60).  
Immunohistochemical analysis revealed that type I, III and 
IV collagens (Fig. 7) and the non-collagenous proteins, like 
fibronectin, laminin and tenascin (Fig. 8), were preserved in d-
HuSk as well. Type I and III collagens resulted scattered 
throughout the entire dermis (Fig. 7, A-D), along with fibronectin 
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(Fig. 8, A-B) and tenascin (Fig. 8, E-F), while type IV collagen 
(Fig. 7, F) and laminin (Fig. 8, D) were localized mostly in the 
basement membrane of vessels. Moreover, type III collagen (Fig. 
7, D) and tenascin formed a delicate texture (Fig. 8, F), while type 
I collagen (Fig. 7, B) and fibronectin (Fig. 8, B) were visible as 
thicker bundles. 
 The investigated ECM components are the main structural 
and functional proteins of cardiac matrix and their retention in d-
HuSk provide evidence to substantiate the ability of d-HuSk to 
deliver a combination of structural support and biological signals 
that act in cardiac microenvironment. Specifically, fibril-forming 
type I and III collagens are the main collagenous component of the 
cardiac matrix (67) that provide tensile strength and are responsible 
for the integrity of cardiac interstitial connective tissue. 
Additionally, type I collagen promotes cardiomyogenesis of MSCs 
(68, 56), while fibronectin, laminin and tenascin, other than 
playing major role in cell adhesion and migration or in tissue 
repair, are involved in embryonic development of the heart (69-
71). Particularly, fibronectin is required during cardiac 
morphogenesis for the formation of the cardiac outflow tract and 
nodes and it is involved in the differentiation of neural crest cells 
into vascular smooth muscle cells by regulating Notch signaling  
(72), tenascin C is transiently expressed during the development of 
the heart at restricted sites to promote differentiation of 
cardiomyocytes (73), while laminin in the developing heart 
orchestrates the assembly of the cardiac ECM and in the adult heart 
lines the myocardial cells (74). Such functions are collectively of 
strategic importance when considering the application of d-HuSk 
in a stem cell-based cardiac regeneration approach, conferring to d-
HuSk the potential to support and boost cardiac differentiation.  
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Figure 7. Immunodetection of collagen type I, III and IV in d-HuSk. 
Representative images of the immunohistochemical analysis showing the 
presence and localization of the main cardiac collagenous components in d-
HuSk: the fibrillar type I (A, B) and III (C, D) collagen and the collagen type IV 
(E, F) with its typical localization in the basement membrane. (Scale bar: 100 
µm for A, C and E, and 50 µm for B, D and F). 
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Figure 8. Immunodetection of fibronectin, laminin and tenascin in d-HuSk. 
Representative images of the immunohistochemical analysis showing the 
presence and distribution of fibronectin (A, B), laminin (C, D) and tenascin (E, 
F) in d-HuSk. (Scale bar: 100 µm for A, C and E, and 50 µm for B, D and F). 
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3.3 d-HuSk has the potential to deliver mechanical 
stimuli 
When evaluating biological scaffold for regenerative 
medicine applications it is crucial to focus on the main 
requirements that the bioconstruct must fulfil to be eventually 
translated to the clinics. As for myocardium, along with the 
biochemical cues regulating cellular processes, like proliferation, 
differentiation and apoptosis, muscle cells need a compliant matrix 
that allows contraction and relaxation cycles while preserving its 
integrity. Hence, mechanical properties of scaffolds should be 
considered as important as biological signals.  
Other than collagens, also elastin and glycosaminoglycans 
(GAGs) are known to be responsible for the biomechanical 
properties of ECM (75, 76). Particularly, elastin is the dominant 
mammalian elastic protein and, as the main component of elastic 
fibers, is responsible for tissue flexibility (77), while 
glycosaminoglycans (GAG) are highly hydrophilic chains of 
proteoglycans whose significant water-binding capacity confers 
mechanical stability to tissues (78).  
Therefore, we analyzed the retention and distribution of 
elastin and GAGs in d-HuSk by Paraldehyde fuchsin Gomori’s, 
Weigert Van Gieson and Alcian Blue stainings. Then we 
performed comparative analysis between d-HuSk and adult human 
myocardium by quantitative dye-binding assay for elastin and 
GAG content to gain an insight into what might be the mechanical 
properties of d-HuSk with the respect to human myocardium (79). 
Paraldehyde fuchsin Gomori’s (Fig. 9, A and B) and 
Weigert Van Gieson (Fig. 9, C and D) stainings clearly showed the 
presence of elastic fibers in native skin (Fig. 9, A and C), and in d-
HuSk (Fig. 9, B and D), where the retention of elastic fibers 
surrounding well-preserved blood vessels resulted glaringly 
obvious (Fig. 9, B and D, red and yellow arrowheads, 
respectively). Quantitative Fastin Elastin assay not only confirmed 
the presence of elastin in d-HuSk but showed also that elastin 
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content of d-HuSk did not differ significantly from the elastin 
content of native skin 34,2054 ± 2,529 µg/mg of dry tissue in d-
HuSk vs. 37,5772 ± 2,561 µg/mg of dry tissue in HuSk) (Fig. 8, 
E).  
  Similarly, Alcian Blue staining revealed the presence of 
GAGs in native skin (Fig. 10, A), and in d-HuSk (Fig. 10, B), 
while quantitative Blyscan assay confirmed the retention by d-
HuSk of amounts of GAGs that did not differ significantly from 
the content of native skin (76,89 ± 14,22 µg/mg of dry tissue vs. 
100,7 ± 17,36 µg/mg of dry tissue in HuSk) (Fig. 10, C).  
  Conversely, the content of elastin and GAGs differed 
between human myocardium and d-HuSk. Indeed, native human 
myocardium contained significantly (p < 0.05) higher amount of 
elastin when compared to d-HuSk (116,50 ± 6,499 µg/mg of dry 
tissue vs. 34,2054 ± 2,529 µg/mg of dry tissue). Interestingly 
though, the elastin content of d-HuSk did not differ significantly 
from that of d-HuM (34,2054 ± 2,529 µg/mg of dry tissue vs 48,18 
± 9,629 µg/mg of dry tissue) (Fig. 11, A). Although the difference 
observed between d-HuSk and native myocardium must be taken 
into account when evaluating the overall composition of d-HuSk, it 
is of note that, as far as we are concerned, the best substitute for 
cardiac ECM in terms of composition is the decellularized cardiac 
ECM. Therefore, the comparison between d-HuSk and d-HuM is 
more appropriate to assess the suitability of d-HuSk as a scaffold 
for cardiac regenerative medicine. As regards GAGs, instead, 
quantitative analysis revealed a significantly (p < 0.001) lower 
content of GAGs in both native (18,69 ± 2,344 µg/mg of dry 
tissue) and decellularized (12,60 ± 2,300 µg/mg of dry tissue) 
human myocardium, when compared with the content of d-HuSk 
(76,89 ± 14,220 µg/mg of dry tissue) (Fig. 11 B). 
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Figure 9. Histochemical and quantitative analysis of elastin content in 
native human skin (HuSK) and in d-HuSk. A-D: Representative images of the 
histochemical analysis performed by Paraldehyde fuchsin Gomori’s (A, B) and 
Weigert Van Gieson (C, D) stainings showing the presence of elastic fibers in 
the dermis of native skin (A and C) and in d-HuSk (B and D). Patent blood 
vessels surrounded by abundant elastic fibers are apparent in d-HuSk (red and 
yellow arrowheads). (HuSk: native human skin). (Scale bar: 50 µm). E: 
Quantification of elastin showing comparable content of elastin in d-HuSk and 
native skin (HuSk). Data are expressed as mean ± SEM (n = 8). 
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Figure 10. Histochemical and quantitative analysis of GAG content in 
native human skin (HuSK) and in d-HuSk. A and B: Representative images 
of the histochemical analysis performed by Alcian Blue staining and showing by 
the light blue color the presence of GAGs in the dermal connective tissue of 
native skin (A) and in d-HuSk (B). (Scale bar: 50 µm) C: Quantification of 
GAGs showing no statistically significant difference in content of GAGs in d-
HuSk and native skin (HuSk). Data are expressed as mean ± SEM (n = 5). 
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Interestingly, due to the presence of elastin and GAGs d-
HuSk holds the potential to deliver mechanical stimuli that support 
and promote cardiac differentiation (56, 80, 81). 
Indeed, a close relationship between the differentiation of 
cardiac myocytes and the accumulation of elastin in embryoid 
bodies has been recently reported (82), along with the evidence 
that elastin content in the left ventricle of developing mammalian 
heart increases throughout the developmental stages but decreases 
soon after birth probably as a stimulus for complete maturation of 
cardiac myocytes (83). 
Furthermore, the early tubular heart is formed by the 
endocardium and the myocardium with the interposed earliest form 
of cardiac ECM, the cardiac jelly. The cardiac jelly consists 
primarily of collagen, glycoproteins and GAGs (84). At this very 
early stage of cardiac development, by controlling cardiac jelly 
hydration, GAGs play a major role in exerting compressive 
strength on the myocardium that drives cardiac chamber expansion 
(85). Hence the higher content of GAGs in d-HuSk might be 
crucial for both conferring elasticity and driving cardiac 
differentiation. Such hypothesis is supported by both the evidence 
emerging from preliminary studies on mechanical characterization 
that the stiffness of d-HuSk, measured as the elastic modulus at 
increasing levels of strain by uniaxial tensile tests, closely matches 
the range of end diastolic values of human myocardium (86, 87) 
and the evidence that the lack of GAGs in mouse embryo leads to 
severe defects in cardiac chamber formation and loss of 
trabeculation (88). 
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Figure 11. Comparative analysis of the content of elastin and GAGs in 
human myocardium and d-HuSk by quantitative dye-binding assays. A: 
Graphical representation of quantitative analysis of elastin content showing the 
presence of significantly higher content of elastin in native human myocardium 
(HuM) than in decellularized human myocardium (d-HuM) or in d-HuSK (n = 
8). There is no statistically significant difference in the elastin content between 
d-HuM and d-HuSk, instead. B: graphical representation of quantitative analysis 
of GAG content showing significantly higher content of GAGs in d-HuSK. than 
in human myocardium, both native and decellularized (n = 5). There is no 
statistically significant difference in the GAG content between HuM and d-
HuM. Data are expressed as mean ± SEM, asterisks are indicators of p value 
obtained as follows: significant (* p ≤ 0.05) and extremely significant (*** p ≤ 
0.001).  
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3.4 The profile of growth factors of d-HuSk is 
comparable to that of the cardiac native matrix 
Growth factors are signaling molecules known to regulate a 
plethora of tissue and cellular functions and their importance has 
been widely recognized also in tissue engineering (89). The ECM 
is known to function as a storage for growth factors (90) that are 
bound to ECM components like GAGs.  
Therefore, we performed a comparative analysis of the 
growth factor profile of d-HuSk and d-HuM by protein array. 
Interestingly, the analysis revealed that d-HuSk contained, to a 
large extent, the same growth factors of the cardiac native matrix 
(Fig. 12, A-C). Indeed, both d-ECMs contained growth factors, 
like hepatocyte growth factor (HGF), insulin-like growth factor 
(IGF), stem cell factor (SCF), platelet-derived growth factor 
(PDGF) and vascular endothelial growth factor (VEGF), but d-
HuSk resulted enriched with growth factors that were virtually 
absent in d-HuM, like granulocyte-macrophage colony-stimulating 
factor (GMCSF) and transforming growth factor (TGF-beta) and 
also contained significantly higher amount of growth factors like 
basic fibroblast growth factor (bFGF) and epidermal growth factor 
(EGF) (Fig. 12, D). 
These factors have been reported to be involved in a variety 
of cardiac processes. Particularly, HGF in the developing heart, 
influences cardiomyocyte proliferation and differentiation, while in 
the adult heart controls heart homeostasis, prevents oxidative stress 
in normal cardiomyocytes (91) and is thought to act as a modulator 
of cardiac repair (92). Additionally, the ligand-receptor systems 
HGF/Met has been extensively investigated for its role in cardiac 
regeneration and evidence supports its involvement in boosting 
migration, engraftment and commitment of cardiac stem cells (93) 
and in regulating MSC proliferation and differentiation into cardiac 
myocytes (94). 
Similarly, PDGF and VEGF, other than playing a pivotal 
role in promoting and controlling angiogenesis and 
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neovascularization, have been reported to enhance the proliferation 
of MSCs and their differentiation into cardiac myocytes (94-96). 
  SCF is a growth factor abundantly expressed in the normal 
heart and for its ability to mobilize stem cells from the bone 
marrow is an interesting factor for stem cell-mediated cardiac 
repair. A role in controlling and attenuating cardiac remodeling has 
also been proposed for this growth factor (97).  
  An intriguing relationship between IGF-1 and cardiac 
myocytes has emerged from several studies, as IGF-1 has been 
shown to control differentiation, transcription, protein synthesis, 
and cell death of cardiac myocytes (98, 99). Further, IGF have 
cardioprotective functions mediated by the inhibition of 
cardiomyocytes apoptosis (100) and stimulates cardiac muscle 
regeneration mediated by the myocardial adult stem cells (101). 
  As mentioned above, d-HuSk contained significantly higher 
amount of bFGF, EGF, GM-CSF and TGF-beta. These factors are 
also involved in processes like cardiac stem cell migration and 
proliferation (102), cardioblast specification (103), cardiac 
development (104) mobilization and proliferation of endothelial 
progenitor cells (105), cardioprotection (106).  
  The abundance of growth factors in d-HuSk strengthens its 
suitability as a promising tool for cardiac tissue engineering. 
Noteworthily, considering the already described similarities 
between d-HuSk and the native cardiac matrix, d-HuSk might 
alone provide two of the three pillars of tissue engineering (Fig. 5), 
namely the scaffold and the signals, and then be exploited as stand-
alone scaffold to boost cardiac regeneration by recruiting resident 
cardiac progenitor cells, or as a cellularized scaffold by preparing a 
cardiac engineered tissue in vitro with the cell population of 
choice. 
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Figura 12. Analysis and quantification of growth factors evaluated by 
specific protein array. The representative images of membrane array (on the 
left) show that most of the 41 targets were present both in d-HuSk and d-HuM. 
However, it is immediately apparent a higher content of bFGF, EGF, GM-CSF 
and TGF-beta in d-HuSk, as shown by the reference array map in the upper left 
corner. The quantification of the aforementioned factors (on the right) shows 
their significantly higher content in d-HuSk. Each value expresses the mean ± 
SEM (n = 4). Asterisks were used to report significance in each comparison as 
follows: significant (* p < 0.05), very significant (*** p< 0.001). O.D.: optical 
density. 
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3.5 d-HuSk is a suitable environment for the 
engraftment and survival of human Cardiac 
Progenitor Cells (hCPCs) 
 
  In order to be considered suitable for regenerative medicine 
purposes, any scaffold must meet some key requirements with 
biocompatibility being one of them (52). This implies that the 
scaffold must have the ability to attract cells and sustain or 
promote their adhesion and survival exactly like the naturally 
occurring tissue microenvironment.  
  Thus, to evaluate the ability of d-HuSk to serve as a viable 
microenvironment capable of supporting hCPC homing, 
engraftment and survival, we seeded and cultured hCPCs on 600-
μm-thick sections of d-HuSk and cultured them for up to four 
weeks. Additionally, to evaluate the effects of d-HuSk on hCPCs 
survival as compared to those of the cardiac native matrix, we 
seeded and cultured in the same conditions hCPCs on 600-μm-
thick sections of d-HuM as a reference. Last, to assess whether d-
HuSk had the potential to attract resident hCPCs and, then, to be 
used as a cell-free scaffold for cardiac tissue engineering, we 
subjected hCPCs seeded and cultured on d-HuM for four weeks to 
d-HuSk, by placing d-HuSk scaffolds in culture in the close 
proximity of recellularized d-HuM scaffolds.  
  Then, we analyzed by time-lapse microscopy the migration 
of hCPC from d-HuM to d-HuSk, while by the fluorescent staining 
with DAPI and SEM analysis we evaluated the engraftment of 
hCPCs on d-HuSk. Finally, by trypan blue exclusion assay we 
assessed the cell death rate and cell viability of hCPCs cultured on 
d-HuSK and on d-HuM, calculating the mean percentages of dead 
and alive cells over total cells at each timepoint considered. 
  The time-lapse movie obtained at a phase contrast 
microscope, showed the hCPCs migrating from d-HuM towards d-
HuSk. Cells reached d-HuSk within a time ranging between 90 and 
116 hours (Fig. 13). 
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Figure 13. Migration of hCPCs from d-HuM to d-HuSk. Representative 
images at phase contrast microscope showing hCPCs engrated onto d-HuM 
migrating towards d-HuSk at different timepoints. A: time 0, B: after 24 hours, 
C: after 48 hours, D: after 72 hours, and E: after 96 hours. Cells reached d-HuSk 
within 90-116 hours. (Scale bar: 100 µm). 
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  By binding the nuclear DNA the DAPI staining showed the 
presence of hCPCs that engrafted onto d-HuSk either after direct 
seeding or after having migrated in vitro to d-HuSk from d-HuM 
(Fig. 14).  
  SEM analysis not only confirmed the engraftment of hCPC 
on d-HuSk but allowed also to examine the morphology of hCPCs, 
that appeared either as mesenchymal-like cells characterized by 
elongated irregular shape and multiple filopodia or as 
rectangular/polygonal-shaped cells. Further, cell-to-cell contacts 
were apparent in some microscopic fields (Fig. 15). 
  48 hours after seeding the death rate of hCPCs seeded on 
the d-HuM or on d-HuSk did not differ significantly (9.814 ± 
1.792% and 9.112 ± 1.532%, respectively) and on both matrices 
the death rate of hCPC decreased remarkably and progressively 
with time (3.402 ± 0.681% on d-HuM and 3.035 ± 0.529% on d-
HuSK after 72 hours, 2.348 ± 0.779% on d-HuM and 1.857 ± 
0.771% on d-HuSK after 96 hours, 1.2723 ± 0.678% on d-HuM 
and 1.190 ± 0.659% on d-HuSK after 120 hours, 0.750 ± 0.303% 
on d-HuM and 0.688 ± 0.239% on d-HuSK after 144 hours) till it 
reached values well below 1% of total cells, without any 
statistically significant differences between the two matrices (0.257 
± 0.107 % on d-HuM and 0.253 ± 0.104% on d-HuSk). Obviously, 
cell viability showed an inverted trend and increased with time on 
both d-HuM and d-HuSk. Specifically, the mean percentage of 
alive cells resulted 90.186 ± 1.792% and 90.888 ± 1.792% after 48 
hours on d-HuM and d-HuSk, respectively, but then increased up 
to 99.743 ± 0.107% and 99.747 ± 0.107% after 7 days on d-HuM 
and d-HuSk, respectively (Fig. 16). 
  Based on the evidence emerging from the in vitro 
assessment of biocompatibility, d-HuSk environment was as safe 
as the native cardiac environment as demonstrated by the effects 
exerted by d-HuSk on migration, engraftment and survival of 
hCPCs. Moreover, being capable of attracting hCPCs engrafted 
onto cardiac native matrix and of supporting their engraftment, d- 
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HuSk holds great promise as a stand-alone scaffold for cardiac 
tissue engineering applications.  
Figure 14. Fluorescent staining with DAPI of hCPCs engrafted on d-HuSk. 
Representative images showing by the nuclear staining with DAPI and the phase 
contrast microscope the presence of hCPCs engrated onto d-HuSk either after 
direct seeding (A, C, E) or after having migrated to d-HuSk from d-HuM (B, D, 
F). The merged pictures clearly show the distribution of hCPCs in d-HuSk. 
(Scale bar: 50 µm). 
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Fig. 15: SEM analysis of hCPCs engrafted onto d-HuSk. Representative 
images of SEM analysis of hCPC cultured on d-HuSk. White asterisks indicate 
the cells. In (A) two cells clearly spread onto d-HuSk that contact each other are 
shown. In (B) one cell with elongated irregular shape characterized by multiple 
filopodia is shown. This morphology is compatible with mesenchymal-like or 
mesenchymal derived cell. In C and D cells with an elongated 
rectangular/poligonal shape compatible with differentiating cardiomyocytes are 
shown. (Scale bar: 10 µm for A and 2 µm for B, C and D). 
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Figure 16. Quantification of cell death rate and viability of hCPCs on d-
HuSk and d-HuM. Mean death rate and mean viability of hCPC cultured on d-
HuSk or d-HuM, as measured by trypan blue exclusion assay. Cells were 
detached and assayed every day started at day 2 to allow them to attach. Then 
based on the ability of healthy cells to exclude the dye, dead cells were 
recognized by the blue staining with trypan blue and, hence, at any given 
timepoint the number of alive and death cells was obtained, averaged and 
calculated as the mean percentage ± SEM (n = 4). With time cell death rate 
dramatically decreased from around 9% to less than 1%, without any statistically 
significant differences between cells cultured on d-HuM or d-HuSk. 
3.6 hCPCs retain on d-HuSk the potential to 
differentiate towards cardiac myocytes in vitro 
Evidence collected thus far supported the hypothesis that d-
HuSk might constitute a myocardial-like matrix. Loaded with 
signals that direct and control cardiac development and the 
homeostasis of the adult heart, d-HuSk could also be capable of 
supporting and promoting the differentiation of hCPCs into cardiac 
myocytes. 
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  Hence, to assess the suitability of d-HuSk to serve as a 
cardiogenic environment for hCPCs, we analyzed the expression of 
genes specific for cardiac program (GATA4, TBX5) and for 
cardiac myocytes (CX43, CX37, TBX3, TBX5, MEF2C, ACTC1, 
MYH7) in hCPCs cultured on d-HuSk for four weeks by real-time 
PCR. To gain better insight into the possible effects of d-HuSk on 
hCPC expression of cardiac myocyte differentiation markers, we 
used as a reference the expression of the same markers in hCPC 
cultured in the same conditions on d-HuM.  
  Interestingly, from gene expression analysis emerged that 
the transcription of all cardiac specific genes investigated, either 
typical of early or late stages of differentiation, was significantly 
upregulated (p ≤ 0.05) up to two-fold in hCPCs cultured on d-
HuSk for 4 weeks (Fig. 17). 
  Additionally, to confirm the results of gene expression 
analysis, we evaluated at the protein level the expression of the 
cardiac myocyte markers Nkx 2.5, alpha-sarcomeric actin, 
connexin-43, desmin and dystrophin in hCPC cultured on d-HuSk 
for 4 weeks, by immunofluorescence.  
  The immunocytochemical analysis showed the 
immunopositivity in hCPC engrafted onto d-HuSk for the markers 
investigated. Clearly, the main cell population of CPC consisted of 
cells expressing Nkx 2.5 and alpha-sarcomeric actin (Fig. 18), as 
well as desmin, dystrophin and connexin-43 (Fig. 19) that are all 
markers specific for cardiac myocytes. Moreover, the alignment of 
actin filaments is suggestive of striated muscle. even though 
further investigation is needed to demonstrate the electrical 
coupling of the connexin-43 expressing cells in order to 
demonstrate their effective ability to form functional syncytia. 
  Although, based on previously discussed evidence, the 
expression of markers specific for cardiac myocytes by hCPCs 
engrafted onto d-HuSk was predictable, it is yet astounding that 
hCPCs expressed both at gene and protein level markers specific 
for cardiac myocytes on decellularized dermal matrix. Even more 
intriguing  is  the  upregulation   of   gene   transcription   for   such 
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Figure 17. Analysis of gene expression of cardiac myocyte markers. Real-
time PCR analysis of the expression of genes characteristic of cardiac myocytes 
showing an upregulation of the transcription for all markers in hCPCs cultured 
on d-HuSk when compared with hCPCs cultured on d-HuM. Data are expressed 
as mean ± SEM (n = 3). Asterisks are indicators of the p value obtained in each 
comparison as follows: significant (* p ≤ 0.05), very significant (** p < 0.001 
and extremely significant (*** p ≤ 0.001).  
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Fig. 18: Fluorescence microscopy analysis of hCPC cultured on d-HuSk for 
four weeks. Representative images of immunocytochemistry, showing the 
immunopositivity and distribution of Nkx 2.5 and alpha-sarcomeric actin in 
hCPC cultured on d-HuSk. (Scale bar: 5 
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Fig. 19: Confocal microscopy analysis 
of hCPC cultured on d-HuSk for four 
weeks. Representative images of 
immunofluorescence experiments, 
showing the distribution pattern of 
desmin connexin-43 and dystrophin in 
hCPC cultured on d-HuSk.Most of CPC 
expresses such markers. Moreover, the 
actin filaments appear distributed in 
approximately parallel rows. This 
pattern is compatible with 
cardiomyocyte differentiation. In the 
lower panel negative control, obtained 
omitting primary antibodies, is shown. 
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markers, which, along with the morphology of cells observed at the 
SEM, supports the hypothesis that the decellularized human skin 
makes a myocardial-like environment that attracts resident CPCs, 
ensures their survival and sustains their differentiation. 
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4 Conclusions 
In the scenario of an urgent need for more effective therapy 
of ischemic heart disease, tissue engineering has emerged as the 
only therapeutic approach that holds the potential to reestablish the 
structural, biomechanical and functional integrity of ischemic 
myocardium. However, the search for the best-performing and 
cost-effective scaffold capable of recapitulating biological and 
mechanical cues of cardiac microenvironment is still a primary 
goal of cardiac regenerative medicine.  
With the present work we developed and evaluated in vitro 
a biological tool for cardiac regeneration that holds the potential to 
become a powerful alternative for both native matrix and synthetic 
scaffold.  
d-HuSk fulfills the key requirements needed for a scaffold 
to warrant its use in tissue engineering. The biological nature of d-
HuSk ensures a full biodegradability and, indeed, d-HuSk should 
be considered a temporary implant providing support to resident 
cells until its complete replacement by native tissue, as resident 
cells are expected to degrade the ECM and produce their own. 
Furthermore, the dermal ECM provides both sites of attachment 
for cell adhesion and a vascular network critical to ensure diffusion 
of nutrients, and, then, addresses two serious problems related to 
synthetic biomaterials.  
However, the groundbreaking features of d-HuSk are its 
autologous origin and ability to support, in vitro, the engraftment, 
proliferation and differentiation potential of resident human cardiac 
progenitor cells (hCPCs). In fact, using d-HuSk as an autograft 
would imply transplanting a fully compatible scaffold capable of 
averting the immunological response and the risk of rejection that 
affect the heterologous and xenogeneic transplant or implant. 
Additionally, despite the different anatomical site of origin d-HuSk 
proved to be a suitable environment for hCPC, at least as cozy as 
the native one. If proven in vivo, such evidence has a tremendous 
potential, as d-HuSK might be used as an autologous and stand-
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alone scaffold that promotes and sustains cardiac regeneration by 
resident hCPCs. Noticeably yet, as adult fibroblasts have been 
recently successfully reprogrammed to cardiac mature cells (107), 
the preparation of scaffolds of decellularized dermal ECM holds 
great promise to eventually evolve into the development of a 
complex therapeutic approach that offers, with one single 
intervention of skin harvesting, the possibility of constructing an 
engineered – fully autologous – myocardium using cardiac direct 
reprogramming of fibroblast to restore the cellular compartment 
and the decellularized dermal ECM to replace the extracellular 
compartment. 
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5 Limitations of the study 
In this study we mainly focused on the effects of d-HuSk 
on CPCs, however further investigation is needed to provide more 
extensive insights on cell-matrix cross-talk and, specifically, to 
analyze whether and at to what extent CPCs can modify the 
composition of d-HuSk and adapt it to their requirements. This 
should include elucidating whether CPCs are capable to remodel 
and to convert d-HuSk from a fetal-like cardiac matrix to a mature 
cardiac matrix. 
The native ECM influences cell behavior by its biological, 
chemical, physical and mechanical properties. Thus, a mechanical 
characterization at the macro and the micro scale should be 
performed to gain better knowledge of the signaling that are 
possibly delivered by d-HuSk and that might influence cell 
viability, proliferation, migration and differentiation. 
Although the evidence that CPCs retain their ability to 
differentiate on biological scaffold obtained from different and 
more easily accessible ECM represents an important advance in 
cardiovascular regenerative medicine, as it overcomes problems 
related to the preparation of myocardial biological scaffolds, such 
evidence emerges from an in vitro study. Undoubtedly, in vivo 
studies designed to understand also mechanical properties, should 
advance its clinical utility.  
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6 Materials and methods 
6.1 Tissue specimens 
Skin specimens were collected from patients undergoing 
abdominoplasty (n = 8, mean age 42.25 ± 7.94 years). Upon 
receipt, specimens were washed in physiological saline, then 
subcutaneous fat tissue was removed, and multiple samples were 
cut. Resulting samples were then promptly processed for 
histological analysis, decellularization, or snap frozen until use. 
Cardiac specimens were harvested from macroscopically uninjured 
areas of the free wall of the left ventricle of hearts of cardiac 
transplant recipients (n = 10, mean age 49.5 ± 4,7 years). 
Specimens were washed in physiological saline and then cut into 
multiple samples that were processed for decellularization, or 
enzymatically digested to isolate hCPCs, or snap-frozen until use. 
Patients provided written informed consent and specimens were 
collected without patient identifiers, following protocols approved 
by the hospital and in conformity with the principles outlined in the 
Declaration of Helsinki.  
6.2 Decellularization of human skin 
Human Skin (HuSk) specimens were cut into smaller 
samples (2 x 1 cm, length by width) and incubated in 
decellularizing solution containing 1% SDS (w/v) and 1% Triton 
(v/v), for 24 hours under constant stirring. The solution was 
replaced every 8 hours. During the procedure the epidermis 
detached from the dermis and was removed. Samples were then 
rinsed for 24 hours in antibiotic solution containing 0.25 μg/ml 
Amphotericin B, 100 U/ml Penicillin, 50 U/ml Streptomycin in 
PBS, and then for an additional 30 minutes in sterile bidistilled 
water. After decellularization, samples of d-HuSk were either fixed 
in formalin for paraffin embedding and histological analysis or 
stored at -80°C until use for decellularization and molecular 
analysis. 
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6.3 Decellularization of human myocardium 
 
  Following a recently published protocol (60), frozen 
samples of human myocardium were mounted on a cryostat chuck 
using Tissue Freezing Medium (Leica Microsystems, Wetzlar, 
Germany) and cut into 600-µm-thick sections by a Leica CM1950 
cryostat (Leica Microsystems). Cryosections were collected into 
sterile 50-ml sterile plastic tubes and then incubated for 24 hours in 
decellularizing solution containing 1% SDS (w/v) and 1% Triton 
(v/v). Cryosections were decellularized under constant agitation on 
an orbital shaker. The decellularizing solution was replaced every 
8 hours. Sections were then rinsed for 24 hours in antibiotic 
solution containing 0.25 μg/ml Amphotericin B, 100 U/ml 
Penicillin, 50 U/ml Streptomycin in PBS, and then for an 
additional 30 minutes in sterile bidistilled water. After 
decellularization, sections of d-HuM were either stored at 4°C in 
sterile bidistilled water or at -80°C until use for comparative 
analysis of d-HuSk and d-HuM. 
6.4 Quantitative measurement of DNA content 
 
  Genomic DNA was extracted from frozen native (n = 4) 
and decellularized human skin (n = 6), using the AllPrep 
DNA/RNA Mini Kit (Qiagen, Hilden, Germany), according to the 
manufacturer's instructions. Briefly, tissue samples were lysed and 
homogenized in a highly denaturing buffer containing guanidine-
isothiocyanate. The buffer ensured isolation of intact DNA and 
RNA by inactivating DNases and RNases. Then the passage of 
lysates through an AllPrep DNA spin column allowed selective 
and efficient binding of genomic DNA. The columns were washed 
and pure, ready-to-use, DNA was then eluted. DNA concentration 
was determined by measuring the absorbance at 260 nm using a 
Nanodrop1000 (Thermo Scientific, Waltham, MA, USA) and the 
gDNA band was visualized with agarose electrophoresis. Data 
were averaged and expressed as the mean ng of DNA ± SE per mg 
of dry tissue. 
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6.5 Histochemistry 
Specimens of native skin (n = 8) and d-HuSk (n = 8) were 
fixed in 10% neutral-buffered formalin and then processed for 
paraffin embedding, following a routine procedure. Briefly, 
formalin-fixed samples were dehydrated in an ascending series of 
alcohols, infiltrated with liquid paraffin and then embedded in 
paraffin in molds. Paraffin blocks were then sliced into serial 5-
µm-thick sections that were mounted onto microscope slides. 
Following standard protocols, after deparaffinization and 
rehydration in a descending alcohol series, sections were stained 
with Fast H&E (Hematoxylin and Eosin) staining kit (Bio-Optica, 
Milan, Italy) to evaluate tissue architecture and effectiveness of 
decellularization, with Paraldehyde Fuchsin Gomori’s Method and 
Weigert - Van Gieson Quick Method staining kits (Bio-Optica) to 
detect elastic fibers and with Alcian Blue pH 2,5 staining kit (Bio-
Optica) to detect GAGs and Hyaluronic Acid. Stained sections 
were observed and evaluated by at least three independent 
observers using a light microscope DM2000 Led (Leica 
Microsystems) equipped with the ICC50HD camera (Leica 
Microsystems) for microphotography. 
6.6 Immunohistochemistry 
Paraffin sections of d-HuSk were prepared as described for 
histochemistry and immunostained using indirect 
immunoperoxidase technique to detect the presence and analyze 
the distribution of collagens, fibronectin, tenascin and laminin 
using specific antibodies. The presence and localization of 
antigen‐antibody complexes were revealed by the UltraVision LP 
Detection System HRP Polymer & DAB Plus Chromogen (Thermo 
Scientific, Waltham, MA, USA), following the manufacturer’s 
protocol. First, sections were incubated with UltraVision Hydrogen 
Peroxide Block to reduce non-specific background due to 
endogenous peroxidase. Next, sections were washed in PBS and 
incubated with Ultra Vision Protein Block, to reduce non-specific 
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bindings of antibodies. Then, slides were incubated with primary 
antibodies against human type I collagen, fibronectin, tenascin and 
laminin (all from Sigma-Aldrich, St. Louis, MO, USA). After 
further washes in PBS, sections were incubated with Primary 
Antibody Enhancer, and then with HRP Polymer. Finally, sections 
were incubated with DAB chromogen for the visualization of the 
polymer complex. Nuclei counterstaining with Mayer’s 
hematoxylin (Bio‐Optica, Milan, Italy), dehydration and coverglass 
mounting with Bio Mount mounting medium (Bio‐Optica) were 
the last steps before analysis. All steps were performed at room 
temperature, except for the incubation with primary antibody that 
was performed at 37°C. Stained sections were evaluated and 
documented by at least three independent observers using a light 
microscope DM2000 Led (Leica Microsystems) equipped with an 
ICC50HD camera (Leica Microsystems). 
6.7 Quantitative measurement of elastin 
 
  Elastin was extracted from samples of native skin (n = 8) 
weighting 20 mg each and from samples of d-HuSk (n = 8) and d-
HuM (n = 8) weighting 20 mg each before decellularization. The 
extraction was performed by heating specimens at 100°C for three 
one-hour periods in 0.25M oxalic acid, in accordance with 
manufacturer's directions. Tissue extracts were then assayed in the 
Fastin Elastin Assay quantitative dye-binding method (Biocolor, 
Ltd, Carrickfergus, UK), following instructions provided by 
manufacturer. Briefly, samples were incubated with Elastin 
Precipitating Reagent to allow the precipitation of α-elastin. Dye 
Reagent was then added and the Elastin-Dye complexes that 
formed were exposed to the Dye Dissociation Reagent before 
proceeding with absorbance reading. All samples were tested in 
triplicate and the absorbance was read at 490 nm using the ELx800 
Absorbance Microplate Reader (BioTek Instruments, Winooski, 
VT, USA), and analyzed with Microsoft Excel (Microsoft Corp, 
Redmond, WA, USA) to generate the calibration curve and 
calculate the final concentration of elastin for each absorbance 
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reading. Data were averaged and expressed as the mean amount of 
elastin (µg) ± SE per mg of wet tissue.  
6.8 Quantitative measurement of GAG 
As described for the Fastin Elastin Assay, samples of 20 
mg each of native skin (n = 5) and samples of both d-HuSk (n = 5) 
and d-HuM (n = 5) weighting 20 mg each before decellularization 
were assayed for the quantitative analysis of sGAG content in 
Blyscan Assay (Biocolor, Ltd). All samples were tested in 
triplicate. Assay was performed according to instruction manual 
provided with the kit. Briefly, samples were digested by incubation 
with Papain Extraction Reagent at 65°C for 3 hours. Digested 
samples were then incubated with Blyscan Dye Reagent to allow 
the formation and precipitation of glycosaminoglycan-dye 
complex. The subsequent addition of the Dissociation Reagent to 
samples caused the release of s-Glycosaminoglycan-Bound dye 
whose absorbance was read at 600 nm using the BioPhotometer 
(Eppendorf) and analyzed with Microsoft Excel (Microsoft Corp, 
Redmond, WA, USA) to generate the calibration curve and 
calculate the final concentration of elastin for each absorbance 
reading. Data were averaged and expressed as the mean amount of 
sGAG (µg) ± SE per mg of wet tissue.  
6.9 Growth Factor Array 
d-HuSk and d-HuM samples were lysed in lysis buffer 
containing Tris-HCl, 5Mm EDTA, Triton-X100, 0.01M DTT, 
PMSF, and protease inhibitor cocktail. Protein concentration was 
quantified by a Bradford assay, and then 100 μg of each tissue 
lysate was assayed in the Human Growth Factor Array C1 
(Raybiotech, Norcross, GA, USA). The assay allows the 
simultaneous detection of 41 targets. Following the assay protocol 
supplied with reagents, array membranes were blocked with 
blocking buffer for 30 minutes at room temperature, and then 
incubated with samples at room temperature for 2.5 hours. 
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Membranes were then washed in wash buffer I and in wash buffer 
II and incubated with biotin‐conjugated antibody overnight at 4°C. 
Membranes were washed and incubated with horseradish 
peroxidase (HRP)‐conjugated streptavidin for 2 hours at room 
temperature. One final wash was performed to remove unbound 
reagents. All array steps were carried out with agitation on an 
orbital shaker. Membranes were then developed with the detection 
buffer, exposed to film, and processed by autoradiography. For the 
analysis, arrays were scanned and spot signal densities from 
corresponding images were obtained using ImageJ densitometry 
software (https://imagej.nih.gov/ij/download.html). Final values 
were obtained by subtracting background from the densitometry 
data and normalizing toward the positive control signals. Data 
were expressed as the mean ± SEM. 
6.10 hCPC isolation and culture  
 
  hCPCs were isolated from human cardiac specimens, as 
previously described (15). Briefly, myocardial specimens were 
dissected, minced, and enzymatically disaggregated by incubation 
in 0.25% trypsin (Sigma-Aldrich) for 6 hours at 4°C and in 0.1% 
(w/v) collagenase II (Sigma-Aldrich) for 30 minutes at 37°C. The 
digestion was stopped by adding double volume of HBSS (Sigma-
Aldrich) supplemented with 10% FBS (Sigma-Aldrich). Resulting 
fragments of tissue were further disaggregated by pipetting. Tissue 
debris and cardiomyocytes were then removed by sequential 
centrifugation at 100 g for 2 minutes, passage through a 40-μm cell 
strainer (BD Biosciences, Franklin Lakes, NJ, USA) and 
centrifugation at 400 g for 5 minutes. Obtained cell population was 
then incubated with anti-fibroblast MicroBeads (Miltenyi Biotec, 
Bergisch Gladbach, Germany), to magnetically label fibroblasts 
that were removed loading cells onto a MACS column (Miltenyi 
Biotec) placed in the magnetic field of a MACS separator 
(Miltenyi Biotec), while unlabeled cells ran through the column. 
Hence, the negative fraction of hCPCs was collected and used to 
prepare 3D cultures with d-HuSk and d-HuM. 
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6.11 Preparation of d-ECM scaffolds for 3D cultures 
of hCPCs 
As previously described for myocardium (60), frozen 
specimens of d-HuSk were mounted on a cryostat chuck using 
Tissue Freezing Medium (Leica Microsystems, Wetzlar, 
Germany), sliced into 600-μm-thick sections by a Leica CM1950 
cryostat (Leica Microsystems) and collected in sterile cell culture 
dishes. 600-µm-thick cryosections of d-Husk and d-HuM were 
sterilized by exposure to ultraviolet radiation for 40 minutes and 
rehydrated for 7 days with F12K medium in an incubator at 37° C 
with 5% CO2. d-HuSk and d-HuM sterilized and rehydrated 
cryosections were then stored in standard culture conditions with 
the same medium until their use as 3D scaffolds for the culture of 
hCPCs. 
6.12 In vitro assessment of d-HuSk cytocompatibility 
Sterilized and rehydrated 600-µm-thick cryosections of d-
Husk (n = 4) and d-HuM (n = 4) were cut into smaller fragments to 
fit the wells of the culture plate. The fragments of d-HuSk and d-
HuM were then placed into the wells of sterile 96-well culture 
plates, seeded with 5x104 hCPCs and cultured with Ham's F12 
medium (Sigma-Aldrich) supplemented with 10% FBS (Sigma-
Aldrich), 5% horse serum (Sigma-Aldrich), 10 ng/ml basic 
fibroblast growth factor (bFGF) (Peprotech, Rocky Hill, NJ, USA), 
and 50 IU/ml penicillin G-streptomycin (Sigma-Aldrich) (F12K 
medium) in an incubator at 37° C with 5% CO2. Cell were allowed 
to adhere to the matrices for 48 hours after seeding. Afterwards, 
cell death rate of hCPCs cultured onto d-Husk and d-HuM was 
assessed every 24 hours for one week, using trypan blue exclusion 
assay. Following a previously published protocol (60) every 24 
hours cells were detached from subsets of wells in the multiwell 
plates by incubation with 0.25% trypsin-EDTA solution (Sigma-
Aldrich) for 10 minutes. Trypsin was inactivated by adding culture 
medium and detached cells were collected and centrifuged at 400 g 
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for 5 minutes. Cells were then stained with trypan blue stain (0.4% 
in PBS) (Lonza, Walkersville, MD, USA) for 2 minutes at room 
temperature and counted using a hemocytometer. As previously 
described (60), the assay is based on the ability of alive cells to 
uptake and exclude the dye that allows to recognize them as 
unstained cells among the dead cells that are not capable of 
excluding the dye and stain blue. Thus, the assay allows the 
computation of both cell death rate and cell viability. The 
percentage of both dead and alive cells over total cells for each 
time point and both on d-HuSk and d-HuM was calculated and 
expressed as the mean percentages of the total number of cells ± 
SEM.  
6.13 Assessment of ability of d-HuSk to support 
hCPC engraftment in vitro 
 
  6.5x105 hCPCs were seeded onto 600-µm-thick 
cryosections of d-HuM (n = 5) in sterile 35-mm culture dishes 
sterilized and rehydrated as described above. Cells were then 
cultured with F12K medium in an incubator at 37° C with 5% CO2 
for four weeks. Afterwards, cells adherent to the plastic dishes 
were scraped off with a cell scraper and sterilized and rehydrated 
600-µm-thick cryosections of d-Husk were placed in culture near 
the d-HuM cryosections seeded with hCPCs. Culture dishes 
carrying both seeded d-HuM and unseeded d-HuSk were then 
cultured for four additional weeks with F12K medium at 37° C and 
in the presence of 5% CO2 in a standard incubator or in a stage 
incubator mounted on a phase-contrast microscope. Additionally, 
5x105 hCPCs were seeded onto sterilized and rehydrated 600-µm-
thick cryosections of d-Husk (n = 3) in sterile 35-mm culture 
dishes, and with F12K medium in an incubator at 37° C with 5% 
CO2 for four weeks. Culture dishes were checked every day and 
medium was replaced every 3 days. 
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6.13.1 Live cell imaging analysis of repopulation of d-
HuSk by hCPC residing on d-HuM 
Culture dishes carrying both seeded d-HuM and unseeded 
d-HuSk were cultured with F12K medium at 37° C and in the 
presence of 5% CO2 in a Stage Top Incubator (Okolab, Pozzuoli, 
Italy) mounted on a Nikon Eclipse Ti-E Microscope DS-Qi2 
(Nikon, Tokyo, Japan) for the first week of culture to follow 
possible homing of CPCs from d-HuM to d-HuSk. Live cell 
imaging was employed to document the repopulation of d-HuSk by 
hCPCs residing onto d-HuM acquiring one picture every thirty 
minutes for 120 hours by digital camera (Nikon) and NIS Elements 
software (Nikon). After five days, d-HuSk sections cultured with 
d-HuM sections seeded with hCPCs were fixed in 4% 
paraformaldehyde for 20 minutes at room temperature, then stained 
with DAPI for 15 minutes at room temperature and analyzed by a 
Nikon Eclipse Ti-E Microscope DS-Qi2 (Nikon) to evaluate the 
presence of cells migrated from d-HuM to d-HuSk. 
6.13.2 Scanning Electron microscopy analysis 
Surface ultrastructure of d-Husk cryosections seeded with 
hCPCs was studied by Scanning Electron Microscopy (SEM). 
Briefly, samples fixed in 10% neutral-buffered formalin were 
dehydrated with ascending ethanol series (30 to 100%), subjected 
to Critical Point Dryer (EMITECH K850), mounted on a stub and 
sputtered with platinum-palladium Denton Vacuum (DESK V). 
FESEM (Field-Emission SEM) Supra 40 (ZEISS; EHT = 5.00 kV, 
WD = 22 mm, detector in lens) was used for observation. 
6.14 Analysis of the effects of d-HuSk on hCPC 
myogenic differentiation potential in vitro 
5x105 hCPCs were seeded onto 600-µm-thick cryosections 
of d-HuM (n = 6) and d-Husk (n = 6) in sterile 35-mm culture 
dishes sterilized and rehydrated as described before, and cultured 
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with F12K medium in an incubator at 37° C with 5% CO2 for 4 
weeks. Culture dishes were checked every day and medium was 
replaced every 3 days. 
6.14.1 Gene expression analysis by Real-time PCR 
 
  Total RNA was extracted from hCPCs both migrated (6.13) 
and directly seeded onto d-HuSk (6.13 and 6.14) and cultured for 
four weeks, using Isol-RNA Lysis Reagent (5Prime, Hamburg, 
Germany) following the instructions provided by the manufacturer. 
Similarly, total RNA was extracted from hCPCs cultured on d-
HuM (6.13 and 6.14) for four weeks, to serve as control. RNA was 
dissolved in RNase-free water, and the final concentration was 
determined using a Nanodrop 1000 spectrophotometer (Thermo 
Scientific, Waltham, MA, USA). All RNA samples were checked 
for quality and were considered suitable for gene expression 
profiling experiments. Then, 100 ng of RNA extracted from each 
sample was reverse transcribed into cDNA using a QuantiTect 
Reverse Transcription Kit (Qiagen). Expression of genes specific 
for cardiac myocytes (GATA4, ACTC1, MYH7, CX37, CX43, 
NKX2.5, MEF2C, TBX3 and TBX5) was quantified by real-time 
qPCR using 5Prime Hot MasterMix (5Prime) in Mastercycler ep 
realplex (Eppendorf). Detection was performed by the fluorescence 
dye SYBR Green I. All samples were tested in triplicate with the 
housekeeping gene (GAPDH) to correct for variations in RNA 
quality and quantity. Comparative quantification of target gene 
expression in the samples was performed based on the cycle 
threshold (Ct) normalized to the housekeeping gene. 
6.14.2 Immunofluorescence  
 
  Immunofluorescence was performed on hCPCs cultured on 
d-HuSk for 4 weeks. Samples were fixed in 4% paraformaldehyde 
for 20 minutes at room temperature and then washed in PBS. To 
block non-specific binding from the donkey secondary antibody, 
samples were incubated with 10% donkey serum for 30 minutes at 
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room temperature and then, without washing, with the primary 
antibodies anti-actin (α-sarcomeric) (Sigma-Aldrich), Nkx 2.5, 
(Abcam, Cambridge, UK) for 1 hour at 37°C in a humified 
chamber. Sections were then washed in PBS and incubated with 
matching secondary antibodies conjugated with fluorescein or 
rhodamine (Jackson Immuno-Research Europe, Newmarket, UK) 
for 1 hour at 37°C. Nuclear counterstaining was performed by 
DAPI (Sigma-Aldrich) and sections were covered with a 
coverglass using the VECTASHIELD Antifade Mounting Medium 
(Vector Labs, Burlingame, CA, USA). Microscopic analysis and 
digital microphotography were performed by three independent 
researchers with a Nikon Eclipse Ti-E Microscope DS-Qi2 by NIS 
Elements software (Nikon Instruments, Tokyo, Japan). The 
expression of cardiac myocytes differentiation markers was also 
analyzed by confocal microscopy. Specifically, formalin-fixed 
samples were permeabilized for 3 hours with a permeabilizing 
solution containing 1% BSA and 0.1% Triton in PBS, then blocked 
with 5% donkey serum and incubated overnight with anti-desmin, 
anti connexin-43, or anti-dystrofin antibodies (Sigma-Aldrich). 
Then samples were extensively washed with PBS and incubated 
for 1 hour and 30 minutes with a fluorescein-conjugated donkey 
anti-mouse (Jackson Immuno-Research Europe). Rhodamin-
conjugated phalloidin was used to detect actin cytoskeleton while 
TO-PRO3 iodide fluorescent dye 642/661 (Invitrogen) was used 
for nuclear staining. As a negative control, the primary antibody 
was omitted. Microscopic analysis was performed by a Leica 
Confocal Microscope (Laser Scanning TCS SP2 equipped with 
Kr/Ar and He/Ne lasers) performing optical spatial series with a 
step size of 2µm. 
6.15 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5.0 
(GraphPad Software, La Jolla, CA, USA). Data obtained from the 
analysis of dsDNA content, the growth factor array, trypan blue 
exclusion assay and the Real-time PCR analysis were analyzed 
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using t test, while data obtained from the quantitative analysis of 
elastin and GAG content were analyzed using one-way analysis of 
variance (ANOVA) with Tukey-Kramer post-test. All experiments 
were performed in triplicate and all data were expressed as the 
mean ± SEM. A value of p < 0.05 was used to identify any 
statistically significant differences. 
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